Camelia S. Sima

18.2k total citations · 4 hit papers
169 papers, 13.3k citations indexed

About

Camelia S. Sima is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Camelia S. Sima has authored 169 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Pulmonary and Respiratory Medicine, 80 papers in Oncology and 27 papers in Surgery. Recurrent topics in Camelia S. Sima's work include Lung Cancer Treatments and Mutations (70 papers), Lung Cancer Diagnosis and Treatment (41 papers) and Lung Cancer Research Studies (34 papers). Camelia S. Sima is often cited by papers focused on Lung Cancer Treatments and Mutations (70 papers), Lung Cancer Diagnosis and Treatment (41 papers) and Lung Cancer Research Studies (34 papers). Camelia S. Sima collaborates with scholars based in United States, Japan and United Kingdom. Camelia S. Sima's co-authors include Mark G. Kris, Gregory J. Riely, Valerie W. Rusch, Marc Ladanyi, William D. Travis, Vincent A. Miller, Prasad S. Adusumilli, Maria E. Arcila, Kyuichi Kadota and Natasha Rekhtman and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Journal of the American Statistical Association.

In The Last Decade

Camelia S. Sima

165 papers receiving 13.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

2013 1.9k citations Maria E. Arcila, Natasha Rekhtman et al. Clinical Cancer Research profile →
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations

2011 503 citations Paul K. Paik, Maria E. Arcila et al. Journal of Clinical Oncology profile →
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

2010 485 citations Geoffrey R. Oxnard, Maria E. Arcila et al. Clinical Cancer Research profile →
Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas

2015 416 citations Kyuichi Kadota, Jun‐ichi Nitadori et al. profile →

Peers

Countries citing papers authored by Camelia S. Sima

Since Specialization

Citations

This map shows the geographic impact of Camelia S. Sima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Camelia S. Sima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Camelia S. Sima more than expected).

Fields of papers citing papers by Camelia S. Sima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Camelia S. Sima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Camelia S. Sima. The network helps show where Camelia S. Sima may publish in the future.

Co-authorship network of co-authors of Camelia S. Sima

This figure shows the co-authorship network connecting the top 25 collaborators of Camelia S. Sima. A scholar is included among the top collaborators of Camelia S. Sima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Camelia S. Sima. Camelia S. Sima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis 2024 ·Annals of Oncology ·(unknown), T.B. Powles, Christof Vulsteke, M. Gross Goupil, (unknown), (unknown), (unknown), (unknown), Rafael Morales‐Barrera, (unknown), (unknown), (unknown), Peter J. Goebell, Francis Boateng, (unknown), Lin Wang, Camelia S. Sima, (unknown), (unknown), (unknown)	4
2	Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis 2020 ·Haemophilia ·(unknown), Felipe A. Castro, J Black, Steve Chaplin, (unknown), (unknown), Camelia S. Sima, Jamie O’Hara	24
3	Long‐term outcomes from prophylactic or episodic treatment of haemophilia A: A systematic review 2018 ·Haemophilia ·Jamie O’Hara, Camelia S. Sima, (unknown), (unknown), Paula Chu, (unknown)	20
4	Vismodegib Use in Clinical Practice: Analysis of a United States Medical Claims Database. 2018 ·PubMed ·C. William Hanke, Shivani K. Mhatre, (unknown), (unknown), Ivor Caro, (unknown), Keith Dawson, Camelia S. Sima	2
5	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases 2015 ·Cancer Discovery ·Paul K. Paik, Ronglai Shen, Helen Won, Natasha Rekhtman, Lu Wang, Camelia S. Sima, Arshi Arora, Venkatraman Seshan, Marc Ladanyi, Michael F. Berger, Mark G. Kris	111
6	Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤3 cm: accuracy and interobserver agreement 2014 ·Histopathology ·Yi‐Chen Yeh, Jun‐ichi Nitadori, Kyuichi Kadota, Akihiko Yoshizawa, Natasha Rekhtman, André L. Moreira, Camelia S. Sima, Valerie W. Rusch, Prasad S. Adusumilli, William D. Travis	112
7	Long-Term Central Venous Catheter Use and Risk of Infection in Older Adults With Cancer 2014 ·Journal of Clinical Oncology ·Allison Lipitz‐Snyderman, Kent A. Sepkowitz, Elena B. Elkin, Laura C. Pinheiro, Camelia S. Sima, (unknown), Coral L. Atoria, Peter B. Bach	26
8	Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma 2013 ·Clinical Cancer Research ·Stefan S. Kachala, Adam J. Bograd, Jonathan Villena‐Vargas, Kei Suzuki, Elliot L. Servais, Kyuichi Kadota, Joanne Chou, Camelia S. Sima, Eva Vertes, Valerie W. Rusch, William D. Travis, Michel Sadelain, Prasad S. Adusumilli	132
9	Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker 2012 ·Clinical Cancer Research ·M. Catherine Pietanza, Kyuichi Kadota, Kety Huberman, Camelia S. Sima, John J. Fiore, (unknown), William D. Travis, Adriana Heguy, Michelle S. Ginsberg, Andrei I. Holodny, Timothy A. Chan, Naiyer A. Rizvi, Christopher G. Azzoli, Gregory J. Riely, Mark G. Kris, Lee M. Krug	122
10	Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal Adenocarcinoma 2012 ·Cancer Epidemiology Biomarkers & Prevention ·Nabil P. Rizk, Elliot L. Servais, Laura H. Tang, Camelia S. Sima, Hans Gerdes, Martin Fleisher, Valerie W. Rusch, Prasad S. Adusumilli	35
11	Vitamin D Receptor Gene Haplotypes and Polymorphisms and Risk of Breast Cancer: A Nested Case–Control Study 2012 ·Cancer Epidemiology Biomarkers & Prevention ·Lawrence S. Engel, Irene Orlow, Camelia S. Sima, Jaya M. Satagopan, Urvi Mujumdar, Pampa Roy, Sarah Yoo, Dale P. Sandler, Michael C.R. Alavanja	36
12	Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients 2012 ·Clinical Cancer Research ·Elliot L. Servais, Christos Colovos, (unknown), Adam J. Bograd, Jun‐ichi Nitadori, Camelia S. Sima, Valerie W. Rusch, Michel Sadelain, Prasad S. Adusumilli	151
13	C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment 2011 ·Cancer Prevention Research ·Andrew T. Chan, Camelia S. Sima, Ann G. Zauber, Paul M. Ridker, Ernest T. Hawk, Monica M. Bertagnolli	18
14	Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling 2011 ·Molecular Cancer Therapeutics ·Jamie E. Chaft, Maria E. Arcila, Paul K. Paik, Christopher Lau, Gregory J. Riely, M. Catherine Pietanza, Maureen F. Zakowski, Valerie W. Rusch, Camelia S. Sima, Marc Ladanyi, Mark G. Kris	162
15	Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations breakdown → 2011 ·Journal of Clinical Oncology ·Paul K. Paik, Maria E. Arcila, Michael Fara, Camelia S. Sima, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Gregory J. Riely	503
16	Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes 2011 ·Journal of Clinical Oncology ·Geoffrey R. Oxnard, Binsheng Zhao, Camelia S. Sima, Michelle S. Ginsberg, Leonard P. James, Robert A. Lefkowitz, Pingzhen Guo, Mark G. Kris, Lawrence H. Schwartz, Gregory J. Riely	118
17	Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib 2011 ·Clinical Cancer Research ·Geoffrey R. Oxnard, Yelena Y. Janjigian, Maria E. Arcila, Camelia S. Sima, (unknown), Gregory J. Riely, William Pao, Mark G. Kris, Marc Ladanyi, Christopher G. Azzoli, Vincent A. Miller	50
18	Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation breakdown → 2010 ·Clinical Cancer Research ·Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima, Gregory J. Riely, Juliann Chmielecki, Mark G. Kris, William Pao, Marc Ladanyi, Vincent A. Miller	485
19	Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma 2010 ·Journal of Clinical Oncology ·Craig H. Moskowitz, Heiko Schöder, Julie Teruya‐Feldstein, Camelia S. Sima, Alexia Iasonos, Carol S. Portlock, David J. Straus, Ariela Noy, Maria Lia Palomba, Owen A. O’Connor, Steven M. Horwitz, Sarah A. Weaver, (unknown), Daniel A. Filippa, James F. Caravelli, Paul A. Hamlin, Andrew D. Zelenetz	225
20	Similar Outcomes among Black and White Renal Allograft Recipients 2008 ·Journal of the American Society of Nephrology ·Karen Yeates, Natasha Wiebe, John Gill, Camelia S. Sima, Douglas E. Schaubel, David C Holland, Brenda R. Hemmelgarn, Marcello Tonelli	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact